MONTREAL, April 05, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.
Full Year 2022 and Recent Highlights:
- Listing on NASDAQ.
- Bolstered balance sheet with cash and cash and cash equivalents of $21 million.
- Acquisition of Nora Pharma Inc. in October 2022, giving the Company 49 prescription drugs on the market in Canada.
- Expansion of proprietary drug development program including the signing of agreements with the University of Arizona for SBFM-PL4 COVID-19 treatment and the Jewish General Hospital (Montreal, Canada) for IND-enabling studies of Adva-27a anticancer compound.
- Advancing the development of the Company's anticancer K1.1 mRNA program by entering into collaboration and testing agreement with one of the leading lipid nanoparticle formulation companies in North America.
- Increased sales from $228,426 in 2021 to $4,345,603 in 2022, largely due to inclusion of the 72 days of Nora Pharma operations, the time since the closing of the acquisition.
"We are delighted with our accomplishments in 2022 and look forward to continuing to build value for our shareholders in 2023 and beyond," said Camille Sebaaly, CFO of Sunshine Biopharma.
About Sunshine Biopharma
Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 54 generic prescription drugs on the market in Canada and 44 employees. The Company is planning to expand its product offering to 86 generic pharmaceuticals over the next two years. In parallel, Sunshine Biopharma is continuing its drug development program which is comprised of (i) K1.1 mRNA for liver cancer, (ii) Adva-27a, a small chemotherapy molecule for pancreatic cancer, and (iii) PLpro inhibitor for COVID-19. For more information, please visit:
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For Additional Information:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma Media Contact:
Christine Petraglia
TraDigital IR
Direct Line: 917-633-8980
investors@sunshinebiopharma.com
蒙特利爾,2023年4月5日(環球網)--陽光生物製藥公司(納斯達克代碼:“SBFM”),一家在腫瘤和抗病毒藥物等多種治療領域提供和研究救命藥物的製藥公司,今天宣佈了截至2022年12月31日的財年的經營業績和最近的亮點。
2022年全年和最近的亮點:
- 在納斯達克上掛牌。
- 通過2100萬美元的現金和現金及現金等價物支持資產負債表。
- 2022年10月收購了Nora Pharma Inc.,使該公司在加拿大市場上擁有49種處方藥。
- 專利藥物開發計劃的擴大,包括與亞利桑那大學簽署了新冠肺炎SBFM-PL4治療協定,以及與猶太綜合醫院(加拿大蒙特利爾)簽署了使IND能夠研究ADVA-27A抗癌化合物的協定。
- 通過與北美領先的脂質納公制劑公司之一達成合作和測試協定,推動公司抗癌K1.1mRNA計劃的發展。
- 銷售額從2021年的228,426美元增加到2022年的4,345,603美元,這主要是由於計入了Nora Pharma的72天運營,也就是收購完成後的時間。
陽光生物醫藥公司首席財務官卡米爾·塞巴利表示:“我們對2022年取得的成就感到高興,並期待著在2023年及以後繼續為我們的股東創造價值。”
關於陽光生物醫藥
陽光生物製藥公司最近收購了Nora Pharma Inc.,因此,該公司目前在加拿大市場上有54種非專利處方藥和44名員工。該公司計劃在未來兩年內將其產品供應擴大到86種仿製藥。與此同時,陽光生物仍在繼續其藥物開發計劃,該計劃包括(I)治療肝癌的K1.1mRNA,(Ii)治療胰腺癌的小化學分子Adva-27A,以及(Iii)治療新冠肺炎的PLPro抑制劑。如需更多資訊,請訪問:
安全港前瞻性陳述
本新聞稿包含前瞻性陳述,這些陳述基於陽光生物醫藥公司(“本公司”)目前的預期、預測和假設。這些前瞻性陳述涉及風險和不確定因素,可能導致實際結果和結果與預期或預期的大不相同。這些陳述出現在本新聞稿中,包括所有與公司的意圖、信念或當前預期有關的非歷史事實陳述,包括與公司的藥物開發活動、財務業績和未來增長有關的陳述。這些風險和不確定性在該公司提交給美國證券交易委員會(美國證券交易委員會)的檔案和報告中有進一步的描述。某些事件的實際結果和時間可能與前瞻性陳述中預測的或預期的大不相同,原因是公司在提交給美國證券交易委員會的檔案中不時詳述的一些因素。茲參考本公司最近提交給美國證券交易委員會的檔案中的警告性聲明和風險因素。
有關其他資訊,請訪問:
陽光Biophma聯繫方式:
首席財務官卡米爾·塞巴利
直撥電話:514-814-0464
郵箱:camille.sebaaly@sunshinebiopharma.com
陽光Biophma媒體聯繫人:
克裡斯汀·佩特拉格裡亞
曲吉紅外線
直撥電話:917-633-8980
郵箱:Investors@sunshinebiopharma.com